Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL1193167 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Biphenyl SCHEMBL28173511 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Biphenyl SCHEMBL7639292 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Biphenyl SCHEMBL27692765 | 0.79 | ALDH1A1 (0.60) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Aniline SCHEMBL28480918 | 0.79 | TSHR (0.55) | ALDH1A1MAPK1CYP1A2HSD17B10TDP1 | |
| Biphenyl SCHEMBL6116263 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Biphenyl SCHEMBL9483986 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Biphenyl SCHEMBL27745920 | 0.78 | ALDH1A1 (0.69) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| Biphenyl SCHEMBL21467263 | 0.78 | ALDH1A1 (0.50) | ALDH1A1MAPK1SLC22A2SLC22A1SLC22A3 | |
| SCHEMBL21496103 | 0.77 | TSHR (0.67) | ALDH1A1MAPK1KIF11CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120022242-A | Multifunctional nano preparation for reversing tumor immunity microenvironment and preparation method and application thereof | 浙江大学长三角智慧绿洲创新中心 | 2025-05-23 | — | — | CN | claimed |
| CN-119285689-A | Galactoside antitumor prodrug intermediate, and preparation and application thereof | 江南大学 | 2025-01-10 | — | — | CN | claimed |
| CN-116375779-B | Method for stereoselective synthesis of 2' -deoxyribonucleoside | 中国药科大学 | 2024-12-31 | — | — | CN | claimed |
| CN-111205296-B | Oxycodone compound and intermediate and preparation method thereof | 中国科学院上海有机化学研究所 | 2022-10-04 | — | — | CN | claimed |
| CN-110713533-B | 25-hydroxy vitamin D3Antigen and method for producing the same | 杭州隆基生物技术有限公司 | 2021-03-16 | — | — | CN | claimed |
| WO-2021027614-A1 | MODIFIED NUCLEOSIDE AND SYNTHESIS METHOD THEREFOR | 斯微(上海)生物科技有限公司 | 2021-02-18 | — | — | WO | claimed |
| CN-111205296-A | Oxycodone compound and intermediate and preparation method thereof | 中国科学院上海有机化学研究所 | 2020-05-29 | — | — | CN | claimed |
| CN-110713533-A | 25-hydroxy vitamin D3Antigen and method for producing the same | 杭州隆基生物技术有限公司 | 2020-01-21 | — | — | CN | claimed |
| US-20030069414-A1 | Urea nucleosides as therapeutic and diagnostic agents | GILEAD SCIENCES, INC. | 2003-04-10 | — | — | US | claimed |
| US-6143882-A | REACTING A NUCLEOSIDE STARTING MATERIAL CONTAINING A LEAVING GROUP WITH A VINYLSTANNE OF DEFINED FORMULA AND CARBON MONOXIDE IN PRESENCE OF A PALLADIUM CATALYST TO FORM AN ENE-ONE INTERMEDIATE, REACTING WITH AN AMINE, AND ISOLATING | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-11-07 | — | — | US | claimed |
| WO-1997035868-A9 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | — | 1997-12-24 | — | — | WO | claimed |
| WO-1997035868-A1 | UREA NUCLEOSIDES AS THERAPEUTIC AND DIAGNOSTIC AGENTS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-10-02 | — | — | WO | claimed |
| US-12545931-B2 | Method for transfection into cardiomyocytes using cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12479791-B2 | Cationic lipid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-25 | — | — | US | disclosed |
| US-20250197343-A1 | CATIONIC LIPID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | US | disclosed |
| CN-115745884-B | Opioid derivatives, intermediates and process for preparing the same | 绍兴赜军生物医药科技有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-1964713-A | Co-use of dopamine-receptor binding compounds | DARPHARMA INC (US) | 2007-05-16 | — | — | CN | disclosed |
| CN-1886421-A | Hemiasterlin derivatives and uses thereof | EISAI CO LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| US-6150373-A | AMINO-SUBSTITUTED DIHYDROPYRIMIDO(4,5-D)PYRIMIDINONE DERIVATIVES; INHIBITORS OF THE T-CELL TYROSINE KINASE P56LCK; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY/-CARCINOGENIC AGENTS; BRONCHOPULMONARY, DERMATOLOGICAL AND CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| CN-1199338-A | Novel fused isoquinolines as dopamine receptor ligands | PURDUE RESEARCH FOUNDATION (US) | 1998-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197343-A1 | CATIONIC LIPID | NR1H3, NR1H2, NR1H4 | ALDH1A1 2469/4885MAPK1 4137/4885SLC22A2 94/4885 |
| US-12479791-B2 | Cationic lipid | LIPC, NPC1, LPCAT1 | ALDH1A1 1918/4885MAPK1 3447/4885SLC22A2 366/4885 |
| US-12545931-B2 | Method for transfection into cardiomyocytes using cationic lipid | TNNT2, TNNC1, TNNI3 | ALDH1A1 4627/4885MAPK1 1957/4885SLC22A2 448/4885 |
| US-20030069414-A1 | Urea nucleosides as therapeutic and diagnostic agents | NUDT1, ADAR, DUT | ALDH1A1 1549/4885MAPK1 2462/4885SLC22A2 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.